William Blair analyst Sami Corwin has maintained their bullish stance on KYTX stock, giving a Buy rating on October 30.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sami Corwin’s rating is based on Kyverna Therapeutics’ strategic advancements and financial stability. The company has made significant progress with its KYV-101 therapy, particularly in the treatment of stiff person syndrome and generalized myasthenia gravis. The anticipated early 2026 release of pivotal Phase II trial results and the planned submission of a Biologics License Application (BLA) shortly thereafter demonstrate a clear pathway to market.
Additionally, Kyverna’s financial position is robust, with a cash runway expected to support operations into 2027, bolstered by a $150 million loan facility. These factors, coupled with the potential for KYV-101 to become the first FDA-approved CAR-T therapy for autoimmune diseases, underpin the Buy rating. The company’s proactive approach in advancing its pipeline and securing financial resources positions it well for future growth.
According to TipRanks, Corwin is a 5-star analyst with an average return of 25.7% and a 54.82% success rate. Corwin covers the Healthcare sector, focusing on stocks such as uniQure, Kyverna Therapeutics, Inc., and Cabaletta Bio.
In another report released on October 30, Wells Fargo also reiterated a Buy rating on the stock with a $31.00 price target.